Abstract
A series of 3 experiments with Sprague-Dawley rats measured taste reactivity (TR) responses elicited by sucrose that was paired on 5 occasions with various doses of d-amphetamine (0, 1, 2, 5, or 10 mg/kg), nicotine (0, 0.4, 0.8, 1.2, or 2.0 mg/kg), or morphine (0, 2, 8, 20, or 80 mg/kg). The TR responses elicited by flavors paired with each of these drugs were compared with those elicited by flavors paired with lithium. The only doses of d-amphetamine and nicotine that effectively conditioned aversive TR responses were high doses that have also been demonstrated to be incapable of producing a place preference. Extremely high doses of morphine were incapable of producing aversive TR responses. It is suggested that aversive TR responses are only produced by doses of agents that are not reinforcing in other paradigms.
Keywords
AmphetamineNicotineTasteMorphinePsychologyPharmacologyConditioned place preferenceInternal medicineNeuroscienceMedicineDopamine
Affiliated Institutions
Related Publications
Face the Beast and Fear the Face: Animal and Social Fears as Prototypes for Evolutionary Analyses of Emotion
ABSTRACT This paper applies a functional‐evolutionary perspective to fear in the context of encounters with animals and threatening humans. It is argued that animal fear origina...
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
8011 Background: Pembro is a potent anti–PD-1 monoclonal antibody. IPI, an anti–CTLA-4 antibody, has shown activity in advanced NSCLC. In melanoma, combined anti–PD-1 and anti–C...
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
The inhibitory receptor CTLA4 has a key role in peripheral tolerance of T cells for both normal and tumor-associated antigens. Murine experiments suggested that blockade of CTLA...
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.
LBA5 Background: IPI monotherapy (3mg/kg) improved overall survival (OS) in a phase III study of previously treated, unresectable or metastatic melanoma. Current study in 1st li...
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).
4505 Background: Human RCC expresses PD-L1 and has been shown to respond to immune-based therapy. MPDL3280A, a human monoclonal antibody containing an engineered Fc-domain desig...
Publication Info
- Year
- 1991
- Type
- article
- Volume
- 105
- Issue
- 6
- Pages
- 955-964
- Citations
- 73
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
73
OpenAlex
Cite This
Linda A. Parker
(1991).
Taste reactivity responses elicited by reinforcing drugs: A doseesponse analysis..
Behavioral Neuroscience
, 105
(6)
, 955-964.
https://doi.org/10.1037//0735-7044.105.6.955
Identifiers
- DOI
- 10.1037//0735-7044.105.6.955